Zacks Investment Research
29 Oct 2026, 16:50 UTC · 1h ago
Baxter Q3 Earnings Beat on Broad-Based Growth, '26 Outlook Raised
Impact · against what's priced in
Baxter's Q3 2026 results provide a positive catalyst through an EPS beat of 13.7% and broad-based organic revenue growth of 5%. The strong performance in the Advanced Surgery division (12% growth) indicates operational momentum that exceeds consensus estimates.
- BAX+0.60
No priced-in read yet
- In context
Baxter beat Q3 adjusted EPS estimates by 13.7% (58 cents vs 51 cents) and surpassed revenue estimates by 2.5% with $2.98 billion in sales. Growth was broad-based, led by a 12% increase in the Advanced Surgery division.
Read from the article alone
Top 1 mover · tap to explore
